Intro

In this episode, Dr. Michele Matarazzo interviews Prof. Tom Foltynie about the recently published phase 3 clinical trial of exenatide as a disease-modifying therapy for Parkinson’s disease in The Lancet. While the findings were disappointing, ongoing post-hoc analyses aim to understand the discrepancy with previous phase 2 results and explore how they might shape the future of exenatide and other GLP-1 agonists in neurodegenerative disorders. Read the article.